ABSTRACT
AIM: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. PATIENTS AND METHODS: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. RESULTS: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). CONCLUSION: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.
Subject(s)
Epithelium/pathology , HIV Infections/complications , Lymphocele/etiology , Lymphoid Tissue/pathology , Parotid Diseases/etiology , Parotid Gland/pathology , Adolescent , Adult , Aged , Child , Female , Follow-Up Studies , HIV/pathogenicity , HIV Infections/mortality , HIV Infections/therapy , Humans , Lymphocele/mortality , Lymphocele/pathology , Male , Middle Aged , Parotid Diseases/mortality , Parotid Diseases/pathology , Prognosis , Retrospective Studies , Survival Rate , Time Factors , Young AdultABSTRACT
OBJECTIVES: To present case vignettes of unusual pediatric parotid pathologies and discuss management paradigms in the context of these lesions. STUDY DESIGN: Retrospective case series. SETTING: Free-standing, academic tertiary care pediatric hospital. METHODS: All patients over the past 18 months undergoing parotidectomy for a parotid mass were reviewed (N=5). RESULTS: Ages ranged from 17 months to 16 years. All presented with a remarkably similar clinical course, consisting of a persistent parotid mass for more than 3 months which was usually painless. Most (4/5 patients) had been treated with antibiotics prior to Otolaryngology consultation. Fine-needle aspiration (FNA) was performed on 3 patients and was diagnostic in one. Complete excision of the mass was performed in each child through a parotidectomy approach (3 total, 2 lateral lobe). The final pathology showed metastatic neuroblastoma (17 months old), undifferentiated primitive sarcoma (22 months old), mucoepidermoid carcinoma (11 years old), nodular fasciitis (12 years old), and hyperplastic lymph node (16 years old). The patient with neuroblastoma died from complications of bone marrow transplant. CONCLUSIONS: The differential diagnosis for a persistent pediatric parotid mass is expansive and differs from that found in the adult population. As this series highlights, in many cases, it is impossible to discern the pathology, or rule out malignancy, based upon the clinical course, imaging, or FNA results. Surgical excision remains the standard for management of these patients and is both diagnostic and therapeutic. Our anecdotal case series highlights the importance of having a low threshold for parotidectomy in these children.
Subject(s)
Parotid Gland/pathology , Parotid Gland/surgery , Parotid Neoplasms/pathology , Surgical Procedures, Operative/methods , Adolescent , Age Factors , Biopsy, Fine-Needle , Carcinoma, Mucoepidermoid/pathology , Carcinoma, Mucoepidermoid/surgery , Child , Cohort Studies , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Infant , Lymph Nodes/pathology , Lymph Nodes/surgery , Male , Neuroblastoma/pathology , Neuroblastoma/surgery , Parotid Diseases/diagnosis , Parotid Diseases/mortality , Parotid Diseases/pathology , Parotid Diseases/surgery , Parotid Neoplasms/diagnosis , Parotid Neoplasms/mortality , Parotid Neoplasms/surgery , Retrospective Studies , Risk Assessment , Sarcoma/diagnosis , Sarcoma/pathology , Survival Rate , Treatment OutcomeABSTRACT
At a single institution over 25 years, 110 patients were operated upon for a mixture of parotid disease. The mean duration of symptoms for benign disease was 40.8 months compared with 15.6 months for malignant disease. Pain was a significant feature of malignant parotid disorders (46.1% compared with 17.8% for benign conditions). The pathology of these masses was diverse, with pleomorphic adenoma being the commonest (44%). Superficial parotidectomy was the commonest procedure employed (69/110) with local excision being performed only prior to 1984 (15/110). There were five cases of permanent facial palsy, all following radical resection for malignancy. One patient developed Frey's syndrome. Recurrence rate for pleomorphic adenomas was 7/48 (15%), three following enucleations prior to 1984. In primary malignancy of the parotid, 3/21 (14%) developed recurrences. Parotid tumours have a low incidence. Surgery for these tumours can be safely performed by those with a special interest in parotid surgery.
